Tagged with NMPA

New Drug Approvals in China Reach Record High in 2023

China New Drug Approvals in China Reach Record High in 2023

China In 2023, the first full year after the COVID-19 pandemic, the National Medical Products Administration (NMPA) set a new record by approving the highest number of new drugs in China in a single year, write Chunrong Yu of Gracell Biotechnologies and Xu Wang of Novo Nordisk (China) Pharmaceuticals in the…

Implementation of China’s Marketing Authorization Holder System: Opportunities and Challenges

China Implementation of China’s Marketing Authorization Holder System: Opportunities and Challenges

China Writing in the August edition of DIA’s Global Forum magazine, Wen Yin of the Pfizer China R&D Center and Wanhe Deng of GSK China Investment look back on four years of China’s marketing authorization holder (MAH)-based regulatory system, including the opportunities it presents, and some of the implementation challenges. …

New Drug Approvals in China 2020

China New Drug Approvals in China 2020

China The Chinese NMPA’s drug approval list for 2020 includes a surge in approvals for locally developed drugs. A total of 46 new drugs were approved in 2020 (less than the 53 approved in 2019), including 28 chemical drugs and 18 biological products. Read more analysis from Xu Wang of Novo…

New Drug Approvals in China in 2020

China New Drug Approvals in China in 2020

China Writing in the February edition of DIA’s Global Forum magazine, Xu Wang of Novo Nordisk Pharma China and Xiaoxi Wang from the Shanghai Center for Drug Evaluation & Inspection analyse the Chinese NMPA’s drug approval list for 2020, including a surge in approvals for locally developed drugs. In the…

China Pharma News Roundup May 4th 2020

China China Pharma News Roundup May 4th 2020

China A selection of recent big stories from Chinese pharma, including Novo Nordisk’s updated China strategy, Chinese biotechs’ funding successes, and some significant regulatory approvals. In Q1 2020, China’s regulator the National Medical Products Administration (NMPA) approved a total of 11 new drugs, 6 imported and 5 domestic Made with Visme…

Other Topics

India

M&A

European Biotech

Cell & Gene Therapy

R&D Section Page